1,331
Views
7
CrossRef citations to date
0
Altmetric
Review

Cystic fibrosis – Ten promising therapeutic approaches in the current era of care

ORCID Icon, ORCID Icon & ORCID Icon
Pages 1107-1124 | Received 01 Jul 2020, Accepted 02 Aug 2020, Published online: 10 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Misganaw Asmamaw & Belay Zawdie. (2021) Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics: Targets and Therapy 15, pages 353-361.
Read now

Articles from other publishers (6)

Tao Zhang, Min Zhang, Liqing Yang, Lingyun Gao & Wei Sun. (2023) Potential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis. Frontiers in Immunology 14.
Crossref
E. A. Sokova, V. V. Arkhipov, A. S. Kazakov, B. K. Romanov, R. N. Alyautdin & M. V. Zhuravleva. (2022) Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring. Safety and Risk of Pharmacotherapy 10:2, pages 110-117.
Crossref
Bin Zhang & Shuixing Zhang. (2022) Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis. European Respiratory Journal 60:1, pages 2103077.
Crossref
E. I. Kondratyeva, E. V. Loshkova, E. D. Nikolaeva, M. M. Khachiyan & G. N. Yankina. (2021) Features of the course and eradication of multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis: clinical case. Meditsinskiy sovet = Medical Council:16, pages 166-173.
Crossref
Christelle Bergeron & André M. Cantin. (2021) New Therapies to Correct the Cystic Fibrosis Basic Defect. International Journal of Molecular Sciences 22:12, pages 6193.
Crossref
Giovanni Taccetti, Michela Francalanci, Giovanna Pizzamiglio, Barbara Messore, Vincenzo Carnovale, Giuseppe Cimino & Marco Cipolli. (2021) Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics 10:3, pages 338.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.